Low-dose glimepiride with sitagliptin improves glycemic control without dose-dependency in patients with type 2 diabetes inadequately controlled on high-dose glimepiride

Endocrine Journal

Volumn 61, Issue 12, 2014, Pages 1163-1170

  Umayahara, Rieko ^a   Yonemoto, Takako ^a   Kyou, Chika ^a   Morishita, Kae ^a   Ogawa, Tatsuo ^a   Taguchi, Yoshitaka ^a   Inoue, Tatsuhide ^a  

^a SHIZUOKA GENERAL HOSPITAL   (Japan)

Author keywords

Combination therapy; Dose dependency; Glycemic control; Low dose glimepiride; Sitagliptin

Indexed keywords

CREATININE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SITAGLIPTIN; TRIACYLGLYCEROL; URIC ACID; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INCRETIN; INSULIN; PYRAZINE DERIVATIVE; SULFONYLUREA DERIVATIVE; TRIAZOLE DERIVATIVE;

AGED; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES CONTROL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; JAPANESE (PEOPLE); LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEIGHT CHANGE; ADVERSE EFFECTS; BLOOD; COHORT ANALYSIS; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHY; DRUG COMBINATION; DRUG EFFECTS; DRUG RESISTANCE; ETHNOLOGY; HYPERGLYCEMIA; JAPAN; KIDNEY; MIDDLE AGED; PATHOPHYSIOLOGY; SECRETION (PROCESS); SEVERITY OF ILLNESS INDEX;

AGED; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; INCRETINS; INSULIN; INSULIN-SECRETING CELLS; JAPAN; KIDNEY; MALE; MIDDLE AGED; PYRAZINES; SEVERITY OF ILLNESS INDEX; SULFONYLUREA COMPOUNDS; TRIAZOLES;

EID: 84919799206     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ14-0233     Document Type: Article

References (17)

1. Seino S (1999) ATP-sensitive potassium channels: a model of heteromultimeric potassium channel/receptor assemblies. Annu RevPhysiol 61: 337-362.
2. Zhang CL, Katoh M, Shibasaki T, Minami K, Sunaga Y, et al. (2009) The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs. Science 325: 607- 610.
3. Drucker DJ (2006) The biology of incretin hormones. Cell Metab 3: 153-165.
4. Aaboe K, Knop FK, Vilsboll T, Vølund A, SimonsenU, et al. (2009) KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. J Clin Endocrinol Metab 94: 603-608.
5. Inagaki N, Iwakura T, Iwamoto Y, Kadowaki T, Seino S, et al. The committee regarding to adequate use for incretin-based therapy (in Japanese). http://www.nittokyo. or.jp/kinkyu_incretin100408m.html.
6. Yasuda H, Sanada M, Kitada K, Terashima T, Kim H, et al. (2007) Rationale and usefulness of newly devised abbreviated diagnostic criteria and staging for diabetic polyneuropathy. Diabetes Res Clin Pract 77 Suppl 1: S178-S183.
7. Harashima SI, Ogura M, Tanaka D, Fukushima T, Wang Y, et al. (2012) Sitagliptin add-on low dosage sulphonylureas: efficacy and safety of combination therapy on glycemic control and insulin secretion capacity in type 2 diabetes. Int J Clin Pract 66: 465-476.
8. Gin H, Rigalleau V (2000) Post-prandial hyperglycemia and diabetes. Diabetes Metab 26: 265-272.
9. Crepaldi G, Del Prato S (1995) What therapy do our NIDDM patients need? Inslin releasers. Diabetes Res Clin Pract 28 Suppl: S159-165.
10. Mukai E, Fujimoto S, Sato H, Oneyama C, Kominato R, et al. (2011) Exendin-4 supresses SRC activation and reactive oxygen species production in diabetic Goto-Kakizaki rat islets in an Epac-dependent manner. Diabetes 60: 218-226.
11. Arai K, Maeda H, Sirabe S, Yamamoto R, Yamauchi M, et al. (2013) Glimepiride strongly enhances the glucose- lowering effect in triple oral antidiabetes therapy with sitagliptin and metformin for Japanese patients with type 2 diabetes mellitus. Diabetes Technol Ther 15: 335-341.
12. Kim SA, Shim WH, Lee EH, Lee YM, Beom SH, et al. (2011) Predictive clinical parameters for the therapeutic efficacy of sitagliptin in korean type 2 diabetes mellitus. Diabetes Metab J 35: 159-165.
13. Nomiyama T, Akehi Y, Takenoshita H, Nagaishi R, Terawaki Y, et al. (2012) Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 95: e27-28.
14. Maeda H, Kubota A, Tanaka Y, Terauchi Y, Matsuba I, et al. (2012) The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes. Diabetes Res Clin Pract 95: e20-22.
15. Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS, et al. (2013) Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia 56: 696-708.
16. Cooperberg BA, Cryer PE (2009) β-cell-mediated signaling predominates over direct α-cell signaling in the regulation of glucagon secretion in humans. Diabetes Care 32: 2275-2280.
17. Monami M, Vitale V, Ambrosio ML, Bartoli N, Toffanello G, et al. (2012) Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials. Adv Ther 29: 736-746.